Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies
Objectives Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post...
| Главные авторы: | , , , , , , , |
|---|---|
| Формат: | Статья |
| Язык: | English |
| Опубликовано: |
BMJ Publishing Group
2023-10-01
|
| Серии: | RMD Open |
| Online-ссылка: | https://rmdopen.bmj.com/content/9/4/e003428.full |
| _version_ | 1827391282079596544 |
|---|---|
| author | Renaud Felten Jacques-Eric Gottenberg Lionel Spielmann Pierre-Marie Duret Laurent Messer Corine Gaillez Weibin Bao Laura Widawski |
| author_facet | Renaud Felten Jacques-Eric Gottenberg Lionel Spielmann Pierre-Marie Duret Laurent Messer Corine Gaillez Weibin Bao Laura Widawski |
| author_sort | Renaud Felten |
| collection | DOAJ |
| description | Objectives Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post hoc analysis using pooled data from the FUTURE 2–5 studies and the MAXIMISE study to further evaluate the impact of hyperuricaemia on clinical presentation/disease severity and response to secukinumab in patients with PsA.Methods Patients were stratified into two groups based on baseline serum uric acid (SUA) level (threshold of 360 µmol/L). A sensitivity analysis was also performed based on SUA thresholds of 300 µmol/L and 420 µmol/L. Demographics, clinical, radiological characteristics and comorbidities data were collected.Results At baseline, patients with hyperuricaemia were mostly male, reported a higher prevalence of hypertension, with more clinical dactylitis, more psoriasis and more severe skin disease compared with patients with normouricaemia. A similar proportion of patients in the normouricaemic and hyperuricaemic cohorts achieved American College of Rheumatology responses, resolution of enthesitis and dactylitis, inhibition of structural damage progression and improvement in health-related quality of life across all secukinumab doses at week 52.Conclusion Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia. Identification of these patients at an early stage may facilitate a personalised treatment approach and improved management of comorbidities. Furthermore, secukinumab provided a rapid and sustained response across all manifestations of PsA up to week 52, irrespective of baseline uricaemia status. |
| first_indexed | 2024-03-08T17:08:38Z |
| format | Article |
| id | doaj.art-31797673311642dcbc0421df10bbeccf |
| institution | Directory Open Access Journal |
| issn | 2056-5933 |
| language | English |
| last_indexed | 2024-03-08T17:08:38Z |
| publishDate | 2023-10-01 |
| publisher | BMJ Publishing Group |
| record_format | Article |
| series | RMD Open |
| spelling | doaj.art-31797673311642dcbc0421df10bbeccf2024-01-04T02:40:08ZengBMJ Publishing GroupRMD Open2056-59332023-10-019410.1136/rmdopen-2023-003428Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studiesRenaud Felten0Jacques-Eric Gottenberg1Lionel Spielmann2Pierre-Marie Duret3Laurent Messer4Corine Gaillez5Weibin Bao6Laura Widawski7Department of Rheumatology, National Reference Centre for Rare East-South-West Autoimmune Systemic Diseases (RESO), Strasbourg University Hospitals, Strasbourg, Grand Est, FranceHôpitaux Universitaires de Strasbourg et Université de Strasbourg, and Centre de Référence pour les Maladies Auto-Immunes Systémiques Rares, CNRS, IBMC, UPR3572, Strasbourg, FranceRheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, FranceRheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, FranceRheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, FranceNovartis Pharma AG, Basel, Basel-Stadt, SwitzerlandNovartis Pharmaceuticals Corporation, East Hanover, New Jersey, USARheumatology Department, Civilian Hospitals Colmar, Colmar, Alsace, FranceObjectives Patients with psoriatic arthritis (PsA) are at a significantly increased risk of hyperuricaemia and development of gout, and those with hyperuricaemia have been found to respond poorly to PsA treatment and have more peripheral and destructive joint damage. We present a comprehensive post hoc analysis using pooled data from the FUTURE 2–5 studies and the MAXIMISE study to further evaluate the impact of hyperuricaemia on clinical presentation/disease severity and response to secukinumab in patients with PsA.Methods Patients were stratified into two groups based on baseline serum uric acid (SUA) level (threshold of 360 µmol/L). A sensitivity analysis was also performed based on SUA thresholds of 300 µmol/L and 420 µmol/L. Demographics, clinical, radiological characteristics and comorbidities data were collected.Results At baseline, patients with hyperuricaemia were mostly male, reported a higher prevalence of hypertension, with more clinical dactylitis, more psoriasis and more severe skin disease compared with patients with normouricaemia. A similar proportion of patients in the normouricaemic and hyperuricaemic cohorts achieved American College of Rheumatology responses, resolution of enthesitis and dactylitis, inhibition of structural damage progression and improvement in health-related quality of life across all secukinumab doses at week 52.Conclusion Patients with PsA and hyperuricaemia have different clinical characteristics from patients with PsA and normouricaemia. Identification of these patients at an early stage may facilitate a personalised treatment approach and improved management of comorbidities. Furthermore, secukinumab provided a rapid and sustained response across all manifestations of PsA up to week 52, irrespective of baseline uricaemia status.https://rmdopen.bmj.com/content/9/4/e003428.full |
| spellingShingle | Renaud Felten Jacques-Eric Gottenberg Lionel Spielmann Pierre-Marie Duret Laurent Messer Corine Gaillez Weibin Bao Laura Widawski Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies RMD Open |
| title | Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies |
| title_full | Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies |
| title_fullStr | Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies |
| title_full_unstemmed | Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies |
| title_short | Impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the FUTURE 2–5 and MAXIMISE studies |
| title_sort | impact of hyperuricaemia on patients with psoriatic arthritis treated with secukinumab in the future 2 5 and maximise studies |
| url | https://rmdopen.bmj.com/content/9/4/e003428.full |
| work_keys_str_mv | AT renaudfelten impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT jacquesericgottenberg impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT lionelspielmann impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT pierremarieduret impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT laurentmesser impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT corinegaillez impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT weibinbao impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies AT laurawidawski impactofhyperuricaemiaonpatientswithpsoriaticarthritistreatedwithsecukinumabinthefuture25andmaximisestudies |